A Phase 3 interventional study of XEN1101 and Placebo in Focal Onset Seizures, sponsored by Xenon Pharmaceuticals Inc.. Recruiting at 103 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Xenon Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.
Among the 395 studies in Seizures with a site in United States, this one is the 28th largest by planned enrollment of the 306 interventional ones that give a count, is one of 17 that started in 2023, is one of 84 in phase 3, reaches primary completion later than 53 of the 91 other live ones, and was the 327th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 13–29
University of Michigan · Sites in United States
Ages 18+
The POLG Foundation · Sites in United States, Australia, Denmark and 6 more countries
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
395 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 83 · Phase 3 94 · Phase 4 36
First in 1975; this study’s year is marked. 17 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 56 across the 306 interventional studies, 99 across the 88 observational. Of the 274 that completed or were terminated, 131 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
173 of 395 have an industry lead sponsor. The 10 most frequent:
Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.
Xenon Pharmaceuticals Inc. has 5 studies filed under Seizures — fewer than ten, so there is no comparison to draw.
36 of the studies in Seizures with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07019922Phase 3Praxis Precision MedicinesA Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | 2026-12 |
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05219617Phase 3SK Life Science, Inc.Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | 2027-02 |
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
Add all 36 to your calendar (.ics) → With an account.
Among the 395 studies in Seizures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo). Eligible subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by 12 weeks of blinded treatment. In order to be included in the study, subjects must be treated with a stable dose of 1 to 3 allowable antiseizure medications (ASMs) for at least one month prior to screening, during baseline, and throughout the double-blind treatment period (DBP) of the study. During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.
Subjects who complete the 12-week DBP will have the opportunity to qualify and enroll in a separate open-label extension (OLE) study for continued treatment with XEN1101. Subjects who do not enroll in the OLE will enter a 8-week post treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
XEN1101 25 mg/day
Drug: XEN1101
XEN1101 15 mg/day
Drug: XEN1101
Placebo
Drug: Placebo
XEN1101 Capsules
Also known as: Azetukalner
Placebo Capsules
Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.
Time frame: From baseline through to the double blind period (week 12).
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency from baseline through the DBP for XEN1101 versus placebo.
Time frame: From baseline through to the double blind period (week 12).
MPC in weekly (7 days) focal seizure frequency from baseline to Week 1 for XEN1101 versus placebo.
Time frame: From baseline through to the week 1.
Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).
Time frame: From baseline through to the double blind period (week 12).
To assess adverse events as criteria for safety and tolerability of XEN1101.
Time frame: From screening through to 56 days post-final dose
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 103 sites across 21 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Jan 2028, 56 months after the start.
Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's planned 56 months is close to that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Oct 2026 → Jan 2028 and completion Dec 2026 → Mar 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XEN1101